Intelligence · Clinical Pipeline
Autoimmune & immunology · Phase III
Autoimmune & immunology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
- Programs
- 368
Quick answer
Autoimmune & immunology Phase III programs: NovaPharmaNews indexes 368 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Takeda 39 programs
- Janssen-Cilag International N.V 26 programs
- Anaxis Pharma 20 programs
- AbbVie 18 programs
- Novartis India 17 programs
- AbbVie Deutschland GmbH 13 programs
- HOFFMANN-LA ROCHE 11 programs
- Eli Lilly and 9 programs
- Chinese Academy of 8 programs
- Bristol-Myers Squibb Australia 7 programs
- PARItec 7 programs
- Pacira Ireland 7 programs
-
Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB
Takeda
Moderate to Severe Plaque Psoriasis
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Ulcerative colitis
1 trial -
Ozanimod, Ozanimod, Ozanimod
Bristol-Myers Squibb Australia Pty Ltd
Moderately to Severely Active Ulcerative Colitis
1 trial -
PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -
Lacuna Pharma Pty Ltd
Systemic lupus erythematosus (SLE)
1 trial -
PF-06438179
Pfizer
Rheumatoid Arthritis
1 trial -
PGET
Atrium Therapeutics
Osteoarthritis
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion
Takeda
Active Ulcerative Colitis (UC) or Crohn's disease (CD)
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion
Takeda
Moderately to severely active Ulcerative Colitis (UC)
1 trial -
PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE
Takeda
Moderately to severely active Crohn's disease (CD)
1 trial -
PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB
Fondazione Telethon ETS
Generalized Myasthenia Gravis
1 trial -
Paeoniflorin + phosphatidylcholine or silymarin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis, Autoimmune
1 trial -
Panzyga 100 mg/ml Infusionslösung, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung
Maze Therapeutics
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
1 trial -
Peficitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis (RA)
1 trial -
Placebo
Sanofi Pasteur
Osteoarthritis
1 trial -
Placebo
AbbVie
Ulcerative Colitis (UC)
2 trials -
Placebo
AbbVie
Psoriatic Arthritis
1 trial -
Placebo
AbbVie
Rheumatoid Arthritis
1 trial -
Placebo
Pfizer
Ulcerative Colitis
1 trial -
Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN
Novartis Pharmaceuticals
generalized Myasthenia Gravis
1 trial -
Placebo 0 mg/1 mL Solution for infusion/injection, VAY736
Novartis Pharmaceuticals
Autoimmune hepatitis
1 trial -
Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection
Vor Biopharma
Generalized Myasthenia Gravis
1 trial -
Placebo de PREDNISONE ARROW 20 mg, PREDNISONE ARROW 20 mg, comprimé sécable
Pari Pharma GmbH
Septic arthritis
1 trial -
Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE
Pari Pharma GmbH
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
1 trial -
Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
1 trial -
Placebo for Adalimumab
AbbVie
Rheumatoid Arthritis
1 trial -
Placebo for Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
Placebo for risankizumab 300mg/3.33ml solution for infusion, ABBV-066 / Risankizumab, Placebo for Risankizumab 90mg/mL Solution for injection in Pre-filled Syringe, Risankizumab, ABBV-066, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Crohn's Disease
1 trial -
Placebo for risankizumab, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Crohn's disease
1 trial -
Placebo injections
Centocor B.V.
Rheumatoid Arthritis
1 trial -
Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab
MoonLake Immunotherapeutics
psoriatic arthritis
1 trial -
Placebo matching Ozanimod hard-gelatin capsules, Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab
Lacuna Pharma Pty Ltd
Moderate to Severe Plaque Psoriasis
1 trial -
Placebo to Descartes-08, Descartes-08
Cartesian Therapeutics
generalized myasthenia gravis
1 trial -
Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Psoriatic arthritis (PsA)
1 trial -
Placebo to MK-7240 (Tulisokibart), tulisokibart
Merck Sharp and Dohme
Crohn’s Disease or Ulcerative Colitis
1 trial -
Placebo to MK-7240, tulisokibart, tulisokibart
Merck Sharp and Dohme
Crohn’s Disease
1 trial -
Placebo to Remibrutinib (LOU064) 00 mg film-coated tablet, LOU064
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
1 trial -
Placebo to Upadacitinib
AbbVie
Rheumatoid Arthritis
1 trial -
Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets
Bristol-Myers Squibb Australia Pty Ltd
Active Psoriatic Arthritis
1 trial -
Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10144
NovoThirteen
Overweight or obesity, and knee osteoarthritis
1 trial -
Platelet Rich Plasma Injection
United Therapeutics Europe Ltd
Osteoarthritis of the Shoulder
1 trial -
Ponesimod
Vanda Pharmaceuticals Netherlands B.V.
Moderate-to-severe Chronic Plaque Psoriasis
1 trial -
Pozelimab + Cemdisiran
Regeneron UK Limited
Generalized Myasthenia Gravis
1 trial -
REGN475
Regeneron UK Limited
Osteoarthritis, Knee
1 trial -
RHB-104
RedHill Biopharma
Crohn's Disease
1 trial -
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
RedHill Biopharma
Crohn Disease
1 trial
Frequently asked questions
How many autoimmune & immunology Phase III programs exist?
368 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs